Genoscience Pharma

In the spring of 2020, Genfit SA very quickly went from a company hoping and planning to be the first to bring a drug therapy for non-alcoholic steatohepatitis (NASH) to market to seeing those dream

Genfit SA took a significant step into its post-non-alcoholic steatohepatitis (NASH) future on 19 September, announcing that it will acquire privately held Versantis AG in a deal enabling it to dev

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Roche/Genentech Bring In Cell Therapy C

It is definitely the season to be jolly for Genfit SA after signing a lucrative licensing deal with fellow French firm Ipsen SA for elafibranor for the rare liver disease primary biliary cholangit